ArticleBMC nephrology2026
Temporal trends in mortality involving chronic lower respiratory disease and chronic kidney disease: evidence from CDC WONDER, 1999-2023.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic Lower Respiratory Disease (CLRD) and chronic kidney disease (CKD) are comorbid progressive diseases that have, over the decades, significantly contributed to high mortality rates. The overlapping mechanisms are aggravated by their coexistence, thus resulting in a poorer prognosis. The purpose of the study is to examine countrywide mortality rates related to CLRD and CKD and to identify the disparities among various population groups.
methodsThe CDC WONDER database was used to discuss age-adjusted mortality rates (AAMRs) of CLRD among patients with chronic kidney disease aged 25 and older, in 1999-2023, by sex and race, by geography, and by metropolitan status. Joinpoint regression was used to calculate Average Annual Percentage Changes (AAPCs) and Annual Percentage Changes (APCs) per 100,000 with 95% confidence intervals (CI).
resultsThere were 242,665 deaths among CKD patients with CLRD between 1999 and 2023. The age-adjusted mortality rate (AAMR) increased from 2.53 (95% CI: 2.46-2.61) in 1999 to 5.07 (95% CI: 4.99-5.16) in 2023, with an overall AAPC of 3.11% (95% CI: 1.91-4.32; p < 0.001). Men had higher AAMRs throughout the study period (AAPC: 2.04%; p = 0.002), while women showed a steeper increase over time (AAPC: 4.26%; p < 0.001). Among racial groups, non-Hispanic Whites had the highest mortality rates (AAPC: 3.62%; p < 0.001). The highest mortality burden was observed in individuals aged ≥ 85 years (AAPC: 4.93%; p < 0.001). Geographically, the Midwest region showed significant increases (AAPC: 3.52%; p < 0.001), with higher mortality observed in non-metropolitan areas (AAPC: 4.20%; p < 0.001).
conclusionThe documented gaps highlight the need to improve healthcare policies, eliminate gaps in coverage, and propagate education and awareness to decrease mortalities. The reduction of the mortalities is essential through addressing the inequalities in healthcare access and increasing health initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.